Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$227.87
+0.2%		$249.03
$186.05
▼
$282.15
$14.18B0.38875,871 shs641,433 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$58.39
+0.8%		$55.91
$33.76
▼
$61.14
$14.47B0.472.02 million shs1.97 million shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$63.46
-1.0%		$69.39
$61.23
▼
$90.87
$5.35B0.491.23 million shs895,553 shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$541.70
-5.2%		$510.30
$409.07
▼
$609.35
$24.51B0.49885,568 shs1.08 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.25%+1.01%-14.75%-16.99%+11.64%
Exelixis, Inc. stock logo
EXEL
Exelixis
+0.78%+0.40%-0.24%+4.55%+41.72%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-1.04%+1.26%-11.60%-23.83%+2.34%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-5.19%+13.93%+10.10%-2.56%+23.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$227.87
+0.2%		$249.03
$186.05
▼
$282.15
$14.18B0.38875,871 shs641,433 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$58.39
+0.8%		$55.91
$33.76
▼
$61.14
$14.47B0.472.02 million shs1.97 million shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$63.46
-1.0%		$69.39
$61.23
▼
$90.87
$5.35B0.491.23 million shs895,553 shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$541.70
-5.2%		$510.30
$409.07
▼
$609.35
$24.51B0.49885,568 shs1.08 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.25%+1.01%-14.75%-16.99%+11.64%
Exelixis, Inc. stock logo
EXEL
Exelixis
+0.78%+0.40%-0.24%+4.55%+41.72%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-1.04%+1.26%-11.60%-23.83%+2.34%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-5.19%+13.93%+10.10%-2.56%+23.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$310.7536.37% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.29-13.88% Downside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.67
Moderate Buy$99.0856.14% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.71
Moderate Buy$621.0014.64% Upside

Current Analyst Ratings Breakdown

Latest PTCT, UTHR, EXEL, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/1/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/25/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$300.00
9/24/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral ➝ Sell$321.00
9/24/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral ➝ Sell$321.00
9/22/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$130.00 ➝ $137.00
9/17/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
9/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$344.00
9/15/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$287.00
9/14/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
9/14/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold ➝ Outperform$98.00
9/11/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M17.45N/AN/A($2.97) per share-76.72
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.44B5.94$3.05 per share19.14$8.06 per share7.24
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$1.73B3.06$8.68 per share7.31($2.56) per share-24.79
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.18B7.30$31.28 per share17.32$164.81 per share3.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8917.6825.52N/A70.99%32.54%7.71%11/11/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.3615.701.7235.33%42.17%31.76%11/3/2026 (Estimated)
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$682.64M-$0.58N/A30.811.98-3.80%N/A-1.32%11/3/2026 (Estimated)
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$27.9519.3818.262.8641.56%20.18%17.98%11/4/2026 (Estimated)

Latest PTCT, UTHR, EXEL, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
8/5/2026Q2 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.86$7.27+$0.41$7.27$804.65 million$783.30 million
7/30/2026Q2 2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.2363$0.92+$0.6837$0.92$298.63 million$360.52 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.39
3.28
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
5.73
5.41

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.30%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
99183.46 million79.04 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.89 million39.20 millionOptionable

Recent News About These Companies

Top Medical Stocks To Consider - September 30th
October 3 at 6:03 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083182
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock
October 3 at 5:23 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082815
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), United Therapeutics (UTHR) and NervGen Pharma (NGEN)
October 3 at 1:34 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MLTX/pressreleases/4934076/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-united-therapeutics-uthr-and-nervgen-pharma-ngen/
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock
October 2 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-ceo-martine-rothblatt-sells-9500-shares-of-stock-2026-10-02/
United Therapeutics (NASDAQ:UTHR) Shares Down 4.1% on Insider Selling
October 2 at 10:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-united-therapeutics-nasdaq-uthr-shares-down-41-on-insider-selling-2026-10-02/
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tango Therapeutics (TNGX), Neurocrine (NBIX) and United Therapeutics (UTHR)
October 2 at 8:27 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NBIX/pressreleases/4925877/analysts-have-conflicting-sentiments-on-these-healthcare-companies-tango-therapeutics-tngx-neurocrine-nbix-and-united-therapeutics-uthr/
United Therapeutics (NASDAQ:UTHR) Stock: Insider Paul Mahon Sells 8,300 Shares
October 2 at 5:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-uthr-insider-buying-and-selling-2026-10-02/
United Therapeutics (NASDAQ:UTHR) CEO Sells $3,926,212.60 in Stock
October 1 at 7:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-ceo-sells-392621260-in-stock-2026-10-01/
Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,689,085.00 in Stock
October 1 at 7:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-united-therapeutics-nasdaq-uthr-evp-sells-468908500-in-stock-2026-10-01/
United Therapeutics Prevails In Patent Litigation Against Liquidia
October 1 at 6:23 PM  |  rttnews.comhttps://www.rttnews.com/3695556/united-therapeutics-prevails-in-patent-litigation-against-liquidia.aspx
United Therapeutics Just Sent Liquidia Stock Lower After Patent Battle
October 1 at 5:11 PM  |  barchart.comhttps://www.barchart.com/story/news/4916627/united-therapeutics-just-sent-liquidia-stock-lower-after-patent-battle
Why United Therapeutics (UTHR) Stock Is Up Today
October 1 at 2:51 PM  |  quiverquant.comQ
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
October 1 at 1:20 PM  |  zacks.comhttps://www.zacks.com/stock/news/2999089/uthr-prevails-in-lqda-s-yutrepia-patent-dispute-stock-up-nearly-13?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2999089
Liquidia Stock Extends Slide Following US Court Ruling in Patent Dispute
October 1 at 12:31 PM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/10/62113623/liquidia-stock-extends-slide-following-us-court-ruling-in-patent-dispute
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
October 1 at 11:49 AM  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/upgrades/26/10/62113057/this-united-therapeutics-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday?utm_source=snapi
United Therapeutics Won Its Patent War and Liquidia Collapsed
October 1 at 11:10 AM  |  247wallst.comhttps://247wallst.com/investing/2026/10/01/united-therapeutics-won-its-patent-war-and-liquidia-collapsed/
United Therapeutics Won Its Patent War and Liquidia Collapsed
October 1 at 11:07 AM  |  247wallst.comhttps://247wallst.com/investing/2026/10/01/united-therapeutics-won-its-patent-war-and-liquidia-collapsed/?utm_source=snapi
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia
October 1 at 8:31 AM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/10/62103103/united-therapeutics-stock-rises-following-federal-court-patent-victory-over-liquidia
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and More
October 1 at 8:31 AM  |  247wallst.comhttps://247wallst.com/investing/2026/10/01/here-are-thursdays-top-wall-street-analyst-research-calls-bp-dollar-tree-exxon-mobil-lennar-occidental-petroleum-rocket-lab-teva-pharmaceuticals-united-therapeutics-and-more/
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia
October 1 at 8:14 AM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/10/62103103/united-therapeutics-stock-rises-following-federal-court-patent-victory-over-liquidia?utm_source=snapi
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?
October 1 at 8:05 AM  |  zacks.comhttps://www.zacks.com/stock/news/2998631/united-therapeutics-uthr-moves-12-6-higher-will-this-strength-last?cid=cs-stocknewsapi-ft-fundamental_analysis|daily_price_change_3%-2998631

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$227.87 +0.56 (+0.25%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$228.00 +0.13 (+0.06%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$58.39 +0.45 (+0.78%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$58.47 +0.08 (+0.14%)
As of 10/2/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$63.46 -0.67 (-1.04%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$63.48 +0.02 (+0.02%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$541.70 -29.68 (-5.19%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$539.70 -2.00 (-0.37%)
As of 10/2/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas